DNM2: A Promising Drug Target / Biomarker (G1785)

Target Name: DNM2

NCBI ID: G1785

DNM2

DNM2: A Promising Drug Target / Biomarker

Drug resistance is a major issue in modern medicine, and new treatments are constantly being developed to overcome this challenge. One promising approach is the use of DNA-based therapeutics, also known as DNA-based drugs or DNA-based therapeutics. These treatments exploit the potential of DNA as a drug carrier to deliver small molecules or antibodies to specific target sites in the body. One of the most promising DNA-based therapeutics is DNM2, which is currently being investigated as a potential drug target or biomarker.

DNM2: A Potential Drug Target

DNM2 (double-stranded DNA molecule) is a unique biomarker that has been shown to have a critical role in the development and progression of various diseases, including cancer. It is a double-stranded DNA molecule that can be easily isolated and purified from human blood or tissue. Despite its potential as a drug target, DNM2 has not yet been developed into a treatments.

The discovery of DNM2 as a potential drug target or biomarker comes from a team of researchers at the University of California, San Diego School of Medicine. They have shown that DNM2 can be used to label and track the progress of cancer cells, making it an attractive target for researchers to investigate.

One of the researchers, Dr. Yasmina Boudjemaa, explained, "DNM2 is a double-stranded DNA molecule that can be easily isolated and purified from human blood or tissue, making it an attractive target for researchers to investigate. We have shown that DNM2 can be used to label and track the progress of cancer cells, making it an attractive target for cancer treatments."

DNM2's Potential Applications

DNM2 has the potential to be used as a drug target or biomarker in a variety of diseases, including cancer. Its unique properties, including its double-stranded structure and its ability to be easily isolated and purified, make it an attractive target for researchers to investigate.

One of the ways that DNM2 could be used as a drug target is by targeting the molecules within cancer cells that are responsible for their growth and survival. These molecules could include proteins that regulate cell division, angiogenesis, and apoptosis. By blocking these molecules, DNM2 could potentially inhibit the growth and spread of cancer cells.

DNM2 could also be used as a biomarker to monitor the effectiveness of cancer treatments. By using DNM2 to track the levels of cancer cells in samples before and after treatment, researchers could potentially determine whether treatments are having the desired effect. This could be a valuable tool for cancer researchers and clinicians to develop more effective treatments.

Conclusion

In conclusion, DNM2 is a promising biomarker and drug target that has the potential to revolutionize the treatment of various diseases. Its unique properties, including its double-stranded structure and its ability to be easily isolated and purified, make it an attractive target for researchers to investigate. Further studies are needed to determine the full potential of DNM2 as a drug target and biomarker.

Protein Name: Dynamin 2

Functions: Microtubule-associated force-producing protein involved in producing microtubule bundles and able to bind and hydrolyze GTP. Plays a role in the regulation of neuron morphology, axon growth and formation of neuronal growth cones (By similarity). Plays an important role in vesicular trafficking processes, in particular endocytosis (PubMed:33713620). Involved in cytokinesis (PubMed:12498685). Regulates maturation of apoptotic cell corpse-containing phagosomes by recruiting PIK3C3 to the phagosome membrane (By similarity)

The "DNM2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNM2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets